沙格列汀对2型糖尿病患者左心室收缩功能影响的研究

Influence of saxagliptin on left ventricular systolic function in type 2 diabetes patients

目的探讨沙格列汀对2型糖尿病患者左心室收缩功能的影响。方法纳入2016年1至12月在新疆医科大学第一附属医院明确诊断为2型糖尿病使用降糖药物治疗的423例患者,根据有无使用沙格列汀治疗分为沙格列汀组和非沙格列汀组,全部行心脏彩超检查,进行组间比较;然后依据左心室射血分数分为收缩功能正常和减退组,进行组间比较;采用Logistic回归分析沙格列汀与左心室收缩功能相关性。结果 (1)与非沙格列汀组患者相比,沙格列汀组患者左心室舒张末径较小[(49.3±6.1)mm vs(52.5±6.6)mm],左心室射血分数较高[(61.6±3.4)%vs(58.4±5.2)%],差异具有统计学意义(P<0.05)。(2)与收缩功能减退患者相比,收缩功能正常患者沙格列汀使用比例较高(51.9%vs 28.1%),同时,收缩功能正常患者左心室舒张末径较小且血压、血糖水平较低,差异具有统计学意义(P<0.05)。(3)采用Logistic回归分析提示,使用沙格列汀为左心室收缩功能的保护因素。结论沙格列汀对2型糖尿病患者左心室收缩功能具有保护作用。

Objective To evaluate the influence of saxagliptin on left ventricular systolic functionin in type2diabetes mellitus(T2DM)patients.Methods A total of423patients with T2DM who had been treated with hypoglycemic agents were collected.Subjects were assigned into either a saxagliptin treatment group or a conventional treatment group.Echocardiography was performed in all subjects,and the results were compared between the two groups.According to left ventricular systolic function,the patients were divided into either a normal or an impaired group,and between-group differences were assessed.Logistic regression analysis was used to evaluation the association of saxagliptin with left ventricular systolic function.Results Compared to the conventional treatment group,patients in the saxagliptin treatment group had significantly smaller left ventricular end-diastolic diameter[(49.3±6.1)mm vs(52.5±6.6)mm,P<0.05],but significantly greater left ventricular ejection fraction(61.6±3.4)%vs(58.4±5.2)%,P<0.05.Compared to patients with left ventricular systolic function impairment,those with normal leftventricular systolic function had significantly higher percentage of saxagliptin usage(51.9%vs28.1%,P<0.05),smaller left ventricular end-diastolic diameter,and lower blood pressure and blood glucose.Logistic regression analysis showed that saxagliptin had a protective effect for left ventricular systolic function.Conclusion Sitagliptin may have the potential value to improve left ventricular systolic function in T2DM patients.